Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 1, 2014, Pages 29-39

  Abbott, Rick ^a   Edwards, Scott ^a   Whelan, Maria ^a   Edwards, Jonathan ^a   Dranitsaris, George ^b  

^a Eastern Regional Integrated Health Authority   (Canada)

^b Health Economics and Biostatistics   (Canada)

Author keywords

community pharmacy; oral anticancer agents; Oral chemotherapy; safety

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; CAPECITABINE; ERLOTINIB; EXEMESTANE; IMATINIB; TEMOZOLOMIDE; WARFARIN;

ACCESS TO INFORMATION; ADULT; AGED; ARTICLE; CANADA; CANCER THERAPY; CLINICAL PRACTICE; CONTINUING EDUCATION; E-MAIL; FEMALE; HEALTH CARE SURVEY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; ONCOLOGY; PATIENT SAFETY; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE;

COMMUNITY PHARMACY; ORAL ANTICANCER AGENTS; ORAL CHEMOTHERAPY; SAFETY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CANADA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PHARMACIES; PHARMACISTS; PROFESSIONAL ROLE; YOUNG ADULT;

EID: 84892931791     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213504975     Document Type: Article

References (24)

1. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008 ; 6: S1 - S14
2. O'Bryant C, Crandell B. Community pharmacists' knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008 ; 48: 632-639
3. O'Neill V, Twelves C. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002 ; 87: 933-937
4. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008 ; 19: 212-222
5. Liu G, Franssen E, Fitch M, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997 ; 15: 110-115
6. Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006 ; 17: 205-210
7. Twelves C, Gollins S, Grieve R, et al. A randomized cross-over trail comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006 ; 17: 239-245
8. Goodin S, Griffith N, Chen B, et al. Safe handling of oral chemotherapeutic agents in clinical practice: Recommendations from an international pharmacy panel. J Oncol Practice. 2011 ; 7: 7-12
9. Pethran A, Schierl R, Hauff K, et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003 ; 76: 5-10
10. Cheung MD, Fishman P, Verma S. Oncology education in Canadian undergraduate and postgraduate training programs. J Cancer Educ. 2009 ; 24: 284-290
11. Abbott R, Edwards S, Edwards J, et al. Anti-cancer agents in the community setting: a survey of pharmacists in Newfoundland and Labrador. Can Pharm J. 2011 ; 144: 220-226
12. Bartel S. Advancing the safe and appropriate use of oral chemotherapy agents American. J Health-Syst Pharmacy. 2007 ; 64: S8 - S14
13. Dillman DA Mail and telephone surveys: the total design method. New York: John Wiley and Sons ; 1978 :
14. Blanchard CG, Ruckdeschel JC, Cohen R, et al. Attitudes toward cancer: the impact of a comprehensive oncology course on second-year medical students. Cancer. 1981 ; 47: 2756-2762
15. Krackov SK, Preston W, Rubin P. Effects of an oncology elective on first-year medical students' knowledge and attitudes about cancer. J Cancer Educ. 1990 ; 5: 43-49
16. De Vries J, Szabo BG, Sleijfer DT. The educational yield of the inter-national summer school "oncology for medical students. J Cancer Educ. 2002 ; 17: 115-120
17. Model Standards of Practice for Canadian Pharmacists, NAPRA 2009, http://napra.ca/Content-Files/Files/Model-Standards-of-Prac-for-Cdn-Pharm- March09-Final-b.pdf (2009).
18. Spoelstra SL, Given CW. Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs. 2011 ; 27: 116-132
19. Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs. 2011 ; 27: 133-141
20. Wolf MS, Davis TC, Shrank W, et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns. 2007 ; 67: 293-300
21. Charpentier M, Orr K, Taveira T. Improving pharmacist knowledge of oral chemotherapy in the community. Ann Pharmacother. 2012 ; 46: 1205-1211
22. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010 ; 28: 2381-2388
23. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 ; 126: 529-537
24. Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011 ; 35: 626-630